Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants

Steven J. Smith, Gary T. Pauly, Aamir Akram, Kevin Melody, Ganesha Rai, David J. Maloney, Zandrea Ambrose, Craig J. Thomas, Joel T. Schneider, Stephen H. Hughes

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a class of antiretroviral compounds that bind in an allosteric binding pocket in HIV-1 RT, located about 10 from the polymerase active site. Binding of an NNRTI causes structural changes that perturb the alignment of the primer terminus and polymerase active site, preventing viral DNA synthesis. Rilpivirine (RPV) is the most recent NNRTI approved by the FDA, but like all other HIV-1 drugs, suboptimal treatment can lead to the development of resistance. To generate better compounds that could be added to the current HIV-1 drug armamentarium, we have developed several RPV analogs to combat viral variants that are resistant to the available NNRTIs. Results: Using a single-round infection assay, we identified several RPV analogs that potently inhibited a broad panel of NNRTI resistant mutants. Additionally, we determined that several resistant mutants selected by either RPV or Doravirine (DOR) caused only a small increase in susceptibility to the most promising RPV analogs. Conclusions: The antiviral data suggested that there are RPV analogs that could be candidates for further development as NNRTIs, and one of the most promising compounds was modeled in the NNRTI binding pocket. This model can be used to explain why this compound is broadly effective against the panel of NNRTI resistance mutants.

Original languageEnglish (US)
Article number11
JournalRetrovirology
Volume13
Issue number1
DOIs
StatePublished - Feb 16 2016
Externally publishedYes

Fingerprint

Rilpivirine
Reverse Transcriptase Inhibitors
HIV-1
Pharmaceutical Preparations
Catalytic Domain
Viral DNA

Keywords

  • Analogs
  • Antiviral activity
  • Binding pocket
  • Doravirine
  • HIV-1
  • Nonnucleoside reverse transcriptase inhibitors
  • Resistance
  • Rilpivirine
  • Susceptibility

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Smith, S. J., Pauly, G. T., Akram, A., Melody, K., Rai, G., Maloney, D. J., ... Hughes, S. H. (2016). Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants. Retrovirology, 13(1), [11]. https://doi.org/10.1186/s12977-016-0244-2

Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants. / Smith, Steven J.; Pauly, Gary T.; Akram, Aamir; Melody, Kevin; Rai, Ganesha; Maloney, David J.; Ambrose, Zandrea; Thomas, Craig J.; Schneider, Joel T.; Hughes, Stephen H.

In: Retrovirology, Vol. 13, No. 1, 11, 16.02.2016.

Research output: Contribution to journalArticle

Smith, SJ, Pauly, GT, Akram, A, Melody, K, Rai, G, Maloney, DJ, Ambrose, Z, Thomas, CJ, Schneider, JT & Hughes, SH 2016, 'Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants', Retrovirology, vol. 13, no. 1, 11. https://doi.org/10.1186/s12977-016-0244-2
Smith, Steven J. ; Pauly, Gary T. ; Akram, Aamir ; Melody, Kevin ; Rai, Ganesha ; Maloney, David J. ; Ambrose, Zandrea ; Thomas, Craig J. ; Schneider, Joel T. ; Hughes, Stephen H. / Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants. In: Retrovirology. 2016 ; Vol. 13, No. 1.
@article{4c43cc7459f84943b03d101b0a56bd39,
title = "Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants",
abstract = "Background: Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a class of antiretroviral compounds that bind in an allosteric binding pocket in HIV-1 RT, located about 10 from the polymerase active site. Binding of an NNRTI causes structural changes that perturb the alignment of the primer terminus and polymerase active site, preventing viral DNA synthesis. Rilpivirine (RPV) is the most recent NNRTI approved by the FDA, but like all other HIV-1 drugs, suboptimal treatment can lead to the development of resistance. To generate better compounds that could be added to the current HIV-1 drug armamentarium, we have developed several RPV analogs to combat viral variants that are resistant to the available NNRTIs. Results: Using a single-round infection assay, we identified several RPV analogs that potently inhibited a broad panel of NNRTI resistant mutants. Additionally, we determined that several resistant mutants selected by either RPV or Doravirine (DOR) caused only a small increase in susceptibility to the most promising RPV analogs. Conclusions: The antiviral data suggested that there are RPV analogs that could be candidates for further development as NNRTIs, and one of the most promising compounds was modeled in the NNRTI binding pocket. This model can be used to explain why this compound is broadly effective against the panel of NNRTI resistance mutants.",
keywords = "Analogs, Antiviral activity, Binding pocket, Doravirine, HIV-1, Nonnucleoside reverse transcriptase inhibitors, Resistance, Rilpivirine, Susceptibility",
author = "Smith, {Steven J.} and Pauly, {Gary T.} and Aamir Akram and Kevin Melody and Ganesha Rai and Maloney, {David J.} and Zandrea Ambrose and Thomas, {Craig J.} and Schneider, {Joel T.} and Hughes, {Stephen H.}",
year = "2016",
month = "2",
day = "16",
doi = "10.1186/s12977-016-0244-2",
language = "English (US)",
volume = "13",
journal = "Retrovirology",
issn = "1742-4690",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants

AU - Smith, Steven J.

AU - Pauly, Gary T.

AU - Akram, Aamir

AU - Melody, Kevin

AU - Rai, Ganesha

AU - Maloney, David J.

AU - Ambrose, Zandrea

AU - Thomas, Craig J.

AU - Schneider, Joel T.

AU - Hughes, Stephen H.

PY - 2016/2/16

Y1 - 2016/2/16

N2 - Background: Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a class of antiretroviral compounds that bind in an allosteric binding pocket in HIV-1 RT, located about 10 from the polymerase active site. Binding of an NNRTI causes structural changes that perturb the alignment of the primer terminus and polymerase active site, preventing viral DNA synthesis. Rilpivirine (RPV) is the most recent NNRTI approved by the FDA, but like all other HIV-1 drugs, suboptimal treatment can lead to the development of resistance. To generate better compounds that could be added to the current HIV-1 drug armamentarium, we have developed several RPV analogs to combat viral variants that are resistant to the available NNRTIs. Results: Using a single-round infection assay, we identified several RPV analogs that potently inhibited a broad panel of NNRTI resistant mutants. Additionally, we determined that several resistant mutants selected by either RPV or Doravirine (DOR) caused only a small increase in susceptibility to the most promising RPV analogs. Conclusions: The antiviral data suggested that there are RPV analogs that could be candidates for further development as NNRTIs, and one of the most promising compounds was modeled in the NNRTI binding pocket. This model can be used to explain why this compound is broadly effective against the panel of NNRTI resistance mutants.

AB - Background: Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a class of antiretroviral compounds that bind in an allosteric binding pocket in HIV-1 RT, located about 10 from the polymerase active site. Binding of an NNRTI causes structural changes that perturb the alignment of the primer terminus and polymerase active site, preventing viral DNA synthesis. Rilpivirine (RPV) is the most recent NNRTI approved by the FDA, but like all other HIV-1 drugs, suboptimal treatment can lead to the development of resistance. To generate better compounds that could be added to the current HIV-1 drug armamentarium, we have developed several RPV analogs to combat viral variants that are resistant to the available NNRTIs. Results: Using a single-round infection assay, we identified several RPV analogs that potently inhibited a broad panel of NNRTI resistant mutants. Additionally, we determined that several resistant mutants selected by either RPV or Doravirine (DOR) caused only a small increase in susceptibility to the most promising RPV analogs. Conclusions: The antiviral data suggested that there are RPV analogs that could be candidates for further development as NNRTIs, and one of the most promising compounds was modeled in the NNRTI binding pocket. This model can be used to explain why this compound is broadly effective against the panel of NNRTI resistance mutants.

KW - Analogs

KW - Antiviral activity

KW - Binding pocket

KW - Doravirine

KW - HIV-1

KW - Nonnucleoside reverse transcriptase inhibitors

KW - Resistance

KW - Rilpivirine

KW - Susceptibility

UR - http://www.scopus.com/inward/record.url?scp=84957934461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957934461&partnerID=8YFLogxK

U2 - 10.1186/s12977-016-0244-2

DO - 10.1186/s12977-016-0244-2

M3 - Article

C2 - 26880034

AN - SCOPUS:84957934461

VL - 13

JO - Retrovirology

JF - Retrovirology

SN - 1742-4690

IS - 1

M1 - 11

ER -